Contrasting LeMaitre Vascular (NASDAQ:LMAT) & Glucose Health (OTCMKTS:GLUC)

Glucose Health (OTCMKTS:GLUC) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Profitability

This table compares Glucose Health and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-108.70%	N/A	N/A
LeMaitre Vascular	22.14%	14.06%	8.78%

Analyst Recommendations

This is a summary of current ratings and price targets for Glucose Health and LeMaitre Vascular, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	0.00
LeMaitre Vascular	0	4	4	0	2.50

LeMaitre Vascular has a consensus price target of $100.20, indicating a potential upside of 17.92%. Given LeMaitre Vascular’s stronger consensus rating and higher possible upside, analysts clearly believe LeMaitre Vascular is more favorable than Glucose Health.

Earnings and Valuation

This table compares Glucose Health and LeMaitre Vascular”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glucose Health	$380,000.00	13.99	-$320,000.00	($0.03)	-8.67
LeMaitre Vascular	$219.86 million	8.77	$44.04 million	$2.32	36.63

LeMaitre Vascular has higher revenue and earnings than Glucose Health. Glucose Health is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 9.5% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Glucose Health has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Summary

LeMaitre Vascular beats Glucose Health on 12 of the 14 factors compared between the two stocks.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.